OncoCyte Management
Management criteria checks 2/4
OncoCyte's CEO is Josh Riggs, appointed in Dec 2022, has a tenure of 1.5 years. total yearly compensation is $724.91K, comprised of 46.9% salary and 53.1% bonuses, including company stock and options. directly owns 0.026% of the company’s shares, worth $10.24K. The average tenure of the management team and the board of directors is 1.4 years and 3.4 years respectively.
Key information
Josh Riggs
Chief executive officer
US$724.9k
Total compensation
| CEO salary percentage | 46.9% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?
Oct 28
Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test
Aug 30Revisiting OncoCyte Corp.
May 04Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?
Jan 25OncoCyte signs an at-the-market agreement to sell $50M of common stock
Jun 14Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt
Jun 02Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like
Mar 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$725k | US$340k | -US$26m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$514k | US$242k | -US$19m |
Compensation vs Market: Josh's total compensation ($USD724.91K) is about average for companies of similar size in the US market ($USD683.97K).
Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.
CEO
Josh Riggs (41 yo)
1.5yrs
Tenure
US$724,910
Compensation
Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$724.91k | 0.026% $ 10.2k | |
| Senior Director | 1.8yrs | US$304.51k | 0% $ 0 | |
| Chief Science Officer | 1.4yrs | US$575.17k | 0.0024% $ 917.1 | |
| Chief Financial Officer | no data | no data | no data | |
| VP, General Counsel & Secretary | less than a year | no data | no data | |
| Senior Vice President of R&D and Product Development | no data | no data | no data | |
| Senior Vice President of Business Operations | less than a year | no data | no data | |
| Scientific Advisor | 8.7yrs | US$328.84k | no data |
1.4yrs
Average Tenure
41yo
Average Age
Experienced Management: OCX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$724.91k | 0.026% $ 10.2k | |
| Lead Independent Director | 1.6yrs | US$97.70k | 0% $ 0 | |
| Independent Chairman | 9yrs | US$112.54k | 0.63% $ 247.2k | |
| Member of Scientific & Medical Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3.4yrs | no data | no data | |
| Independent Director | 8.5yrs | US$92.86k | 0.019% $ 7.3k | |
| Member of Scientific & Medical Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3.4yrs | no data | no data |
3.4yrs
Average Tenure
64.5yo
Average Age
Experienced Board: OCX's board of directors are considered experienced (3.4 years average tenure).